New insights into the treatment of Glanzmann thrombasthenia

Transfusion Medicine Reviews

Volumn 30, Issue 2, 2016, Pages 92-99

  Poon, Man Chiu ^a   Di Minno, Giovanni ^b   d'Oiron, Roseline ^c   Zotz, Rainer ^d  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c BICÊTRE HOSPITAL   (France)

^d Center for Blood Coagulation and Transfusion Medicine   (Germany)

Author keywords

Gene therapy; Glanzmann thrombasthenia; Hematopoietic stem cell transplantation (HSCT); Platelet glycoprotein GPIIb IIIa complex; Platelets; Recombinant activated factor VII (rFVIIa)

Indexed keywords

ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; FIBRIN; FIBRINOGEN RECEPTOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; THROMBOCYTE ANTIBODY; BLOOD CLOTTING FACTOR 7A; RECOMBINANT FVIIA; RECOMBINANT PROTEIN; THROMBOCYTE ANTIGEN;

ANTIBODY PRODUCTION; BLEEDING TIME; BLOOD CLOTTING; BLOODSTREAM INFECTION; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG BINDING; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; FIBRINOLYSIS; GENE MUTATION; GENE THERAPY; GLANZMANN DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION RISK; ITGA2B GENE; ITGB3 GENE; REVIEW; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE TRANSFUSION; TREATMENT RESPONSE; ADVERSE EFFECTS; BIOSYNTHESIS; BLOOD SAFETY; BLOODBORNE BACTERIUM; COMPLICATION; DISEASE MANAGEMENT; FEMALE; HEMORRHAGE; HEMOSTATIC TECHNIQUE; IMMUNOLOGY; MALE; THROMBASTHENIA;

ANTIGENS, HUMAN PLATELET; BLOOD SAFETY; BLOOD-BORNE PATHOGENS; DISEASE MANAGEMENT; FACTOR VIIA; FEMALE; GENETIC THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGE; HEMOSTATIC TECHNIQUES; HUMANS; MALE; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PLATELET TRANSFUSION; RECOMBINANT PROTEINS; THROMBASTHENIA; THROMBIN;

EID: 84960968719     PISSN: 08877963     EISSN: 15329496     Source Type: Journal    
DOI: 10.1016/j.tmrv.2016.01.001     Document Type: Review

References (96)

1. Glanzmann E. Hereditare hamorrhagische Thrombasthenia. Ein Beitrag zur Pathologie der Bluttplattchen. Jarbuch Kinderheilkd 1918, 88:1-42.
2. Caen J.P., Castaldi P.A., Lecrec J.C., Insmann S., Larrieu M.J., Probst M., et al. Congenital bleeding disorders with long bleeding time and normal platelet count. 1. Glanzmann's thrombasthenia (report of fifteen patients). Am J Med 1966, 41:4-26.
3. Bellucci S., Caen J. Molecular basis of Glanzmann's thrombasthenia and current strategies in treatment. Blood Rev 2002, 16:193-202.
4. Nurden A.T. Glanzmann thrombasthenia. Orphanet J Rare Dis 2006, 1:10. 10.1186/1750-1172-1-10.
5. Buyukasik Y., Karakus S., Goker H., Haznedaroglu I.C., Ozatli D., Sayinalp N., et al. Rational use of the PFA-100 device for screening of platelet function disorders and von Willebrand disease. Blood Coagul Fibrinolysis 2002, 13:349-353.
6. Favaloro E.J. Clinical utility of the PFA-100. Semin Thromb Hemost 2008, 34:709-733.
7. Braunsteiner H., Pakesch F. Thrombocytoasthenia and thrombocytopathia-old names and new diseases. Blood 1956, 11:965-976.
8. Reichert N., Seligsohn U., Ramot B. Clinical and genetic aspects of Glanzmann's thrombasthenia in Israel: report of 22 cases. Thromb Diath Haemorrh 1975, 34:806-820.
9. Nurden A.T., Fiore M., Nurden P., Pillois X. Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood 2011, 118:5996-6005.
10. Patel D., Väänänen H., Jirousková M., Hoffmann T., Bodian C., Coller B.S. Dynamics of GPIIb/IIIa-mediated platelet-platelet interactions in platelet adhesion/thrombus formation on collagen in vitro as revealed by videomicroscopy. Blood 2003, 101:929-936.
11. George J.N., Caen J.P., Nurden A.T. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood 1990, 75:1383-1395.
12. Bennett J.S., Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest 1979, 64:1393-1401.
13. di Minno G., Capitanio A.M., Thiagarajan P., Martinez J., Murphy S. Exposure of fibrinogen receptors on fresh and stored platelets by ADP and epinephrine as single agents and as a pair. Blood 1983, 61:1054-1059.
14. Phillips D.R., Charo I.F., Parise L.V., Fitzgerald L.A. The platelet membrane glycoprotein IIb-IIIa complex. Blood 1988, 71:831-843.
15. Xiao T., Takagi J., Coller B.S., Wang J.H., Springer T.A. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature 2004, 432:59-67.
16. Coller B.S., Shattil S.J. The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood 2008, 112:3011-3025.
17. Savage B., Almus-Jacobs F., Ruggeri Z.M. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 1998, 94:657-666.
18. Ni H., Denis C.V., Subbarao S., Degen J.L., Sato T.N., Hynes R.O., et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 2000, 106:385-392.
19. Andre P., Prasad K.S., Denis C.V., He M., Papalia J.M., Hynes R.O., et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 2002, 8:247-252.
20. Toogeh G., Sharifian R., Lak M., Safaee R., Artoni A., Peyvandi F. Presentation and pattern of symptoms in 382 patients with Glanzmann thrombasthenia in Iran. Am J Hematol 2004, 77:198-199.
21. D'Andrea G., Colaizzo D., Vecchione G., Grandone E., Di Minno G., Margaglione M. Glanzmann's thrombasthenia: identification of 19 new mutations in 30 patients. Thromb Haemost 2002, 87:1034-1042.
22. Franchini M., Favaloro E.J., Lippi G. Glanzmann thrombasthenia: an update. Clin Chim Acta 2010, 411:1-6.
23. French D.L. The molecular genetics of Glanzmann's thrombasthenia. Platelets 1998, 9:5-20.
24. Rosenberg N., Yatuv R., Sobolev V., Peretz H., Zivelin A., Seligsohn U. Major mutations in calf-1 and calf-2 domains of glycoprotein IIb in patients with Glanzmann thrombasthenia enable GPIIb/IIIa complex formation, but impair its transport from the endoplasmic reticulum to the Golgi apparatus. Blood 2003, 101:4808-4815.
25. Hoffman M., Monroe D.M., Roberts H.R. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1998, 9(Suppl. 1):S61-S65.
26. Monroe D.M., Hoffman M., Oliver J.A., Roberts H.R. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997, 99:542-547.
27. Weeterings C., De Groot P.G., Adelmeijer J., Lisman T. The glycoprotein Ib-IX-V complex contributes to tissue factor-independent thrombin generation by recombinant factor VIIa on the activated platelet surface. Blood 2008, 112:3227-3233.
28. Lisman T., Moschatsis S., Adelmeijer J., Nieuwenhuis H.K., De Groot P.G. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. Blood 2003, 101:1864-1870.
29. Lisman T., Adelmeijer J., Heijnen H.F., De Groot P.G. Recombinant factor VIIa restores aggregation of alphaIIbbeta3-deficient platelets via tissue factor-independent fibrin generation. Blood 2004, 103:1720-1727.
30. Poon M.-C. Factor VIIa. Platelets 2012, Academic Press, New York. 3rd ed. A.D. Michelson (Ed.).
31. Wilcox D.A., Wautier J.L., Pidard D., Newman P.J. A single amino acid substitution flanking the fourth calcium binding domain of alpha IIb prevents maturation of the alpha IIb beta 3 integrin complex. J Biol Chem 1994, 269:4450-4457.
32. Ruiz C., Liu C.Y., Sun Q.H., Sigaud-Fiks M., Fressinaud E., Muller J.Y., et al. A point mutation in the cysteine-rich domain of glycoprotein (GP) IIIa results in the expression of a GPIIb-IIIa (alphaIIbbeta3) integrin receptor locked in a high-affinity state and a Glanzmann thrombasthenia-like phenotype. Blood 2001, 98:2432-2441.
33. Caen J. Glanzmann's thrombasthenia. Baillières clinical haematology 1972, 383-392. Baillière Tindall, London. 1st ed.
34. Caen J. Glanzmann's thrombasthenia. Baillières clinical haematology 1979, 609-625. Baillière Tindall, London. 2nd ed. J. Caen (Ed.).
35. D'Andrea G., Margaglione M. Glanzmann's thrombasthenia: modulation of clinical phenotype by alpha2C807T gene polymorphism. Haematologica 2003, 88:1378-1382.
36. di Minno G., Zotz R.B., d'Oiron R., Bindslev N., Di Minno M.N., Poon M.C. The international prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes in non-surgical bleeding episodes in Glanzmann thrombasthenia patients. Haematologica 2015, 100:1031-1037.
37. Poon M.C., D' Oiron R., Zotz R.B., Bindlslev N., Di Minno M.N., Di Minno G. The international prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention. Haematologica 2015, 100:1038-1044.
38. Borhany M., Fatima H., Naz A., Patel H., Shamsi T. Pattern of bleeding and response to therapy in Glanzmann thrombasthenia. Haemophilia 2012, 18:e423-e425.
39. Karimi M., Ravanbod S., Cohan N., Ala F. How to deal with medical and social aspects of bleeding disorders-preparing women and the family in developing countries. Haemophilia 2011, 17(Suppl. 1):42-44.
40. Poon M.C., Demers C., Jobin F., Wu J.W. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 1999, 94:3951-3953.
41. NiaStase RT® product monograph [Accessed April 8, 2015]. http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=83251&lang=eng.
42. NovoSeven® RT highlights of prescribing information [Accessed April 8, 2015]. http://www.fda.gov/downloads/%2E%2E%2E/ucm056954.pdf.
43. NovoSeven® summary of product characteristics [Accessed March 3, 2015]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000074/WC500030873.pdf.
44. O'Brien S.F., Yi Q.L., Fan W., Scalia V., Kleinman S.H., Vamvakas E.C. Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services. Transfusion 2007, 47:316-325.
45. Callum J.L., Lin Y., Pinkerton P.H., et al. Bloody easy 3: blood transfusions, blood alternatives and transfusion reactions. A guide to transfusion medicine third edition; Ontario Regional Blood Coordinating Network 2011, http://transfusionontario.org/en/cmdownloads/categories/bloody_easy/. Accessed July 6, 2015.
46. Blajchman M.A., Beckers E.A., Dickmeiss E., Lin L., Moore G., Muylle L. Bacterial detection of platelets: current problems and possible resolutions. Transfus Med Rev 2005, 19:259-272.
47. Vamvakas E.C., Blajchman M.A. Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality. Transfus Med Rev 2010, 24:77-124.
48. Katus M.C., Szczepiorkowski Z.M., Dumont L.J., Dunbar N.M. Safety of platelet transfusion: past, present and future. Vox Sang 2014, 107:103-113.
49. Yomtovian R.A., Palavecino E.L., Dysktra A.H., Downes K.A., Morrissey A.M., Bajaksouzian S., et al. Evolution of surveillance methods for detection of bacterial contamination of platelets in a university hospital, 1991 through 2004. Transfusion 2006, 46:719-730.
50. Jacobs M.R., Good C.E., Lazarus H.M., Yomtovian R.A. Relationship between bacterial load, species virulence, and transfusion reaction with transfusion of bacterially contaminated platelets. Clin Infect Dis 2008, 46:1214-1220.
51. Jenkins C., Ramirez-Arcos S., Goldman M., Devine D.V. Bacterial contamination in platelets: incremental improvements drive down but do not eliminate risk. Transfusion 2011, 51:2555-2565.
52. Annual shot report 2014 [Accessed December 10, 2015]. http://www.shotuk.org/wp-content/uploads/SHOT-2014-Annual-Report_v11-Web-Edition.pdf.
53. Stramer S.L., Hollinger F.B., Katz L.M., Kleinman S., Metzel P.S., Gregory K.R., et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009, 49(Suppl. 2):1S-29S.
54. Vamvakas E.C. Risk-reduction strategies for platelet transfusion in the United States. Sci World J 2011, 11:624-640.
55. Di Minno G., Perno C.F., Tiede A., Navarro D., Canaro M., Guertler L., et al. Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders. Blood Rev 2016, 30:35-48.
56. Murphy M.F., Metcalfe P., Thomas H., Eve J., Ord J., Lister T.A., et al. Use of leucocyte-poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization. Br J Haematol 1986, 62:529-534.
57. Sniecinski I., O'Donnell M.R., Nowicki B., Hill L.R. Prevention of refractoriness and HLA-alloimmunization using filtered blood products. Blood 1988, 71:1402-1407.
58. Slichter S.J. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997, 337:1861-1869.
59. Poon M.C., d'Oiron R., Von Depka M., Khair K., Negrier C., Karafoulidou A., et al. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. J Thromb Haemost 2004, 2:1096-1103.
60. Santoro C., Rago A., Biondo F., Conti L., Pulcinelli F., Laurenti L., et al. Prevalence of allo-immunization anti-HLA and anti-integrin alphaIIbbeta3 in Glanzmann thromboasthenia patients. Haemophilia 2010, 16:805-812.
61. Fiore M., Firah N., Pillois X., Nurden P., Heilig R., Nurden T. Natural history of platelet antibody formation against alphaIIbbeta3 in a French cohort of Glanzmann thrombasthenia patients. Haemophilia 2012, 18:e201-e209.
62. Brand A., Claas F.H., Voogt P.J., Wasser M.N., Eernisse J.G. Alloimmunization after leukocyte-depleted multiple random donor platelet transfusions. Vox Sang 1988, 54:160-166.
63. Legler T.J., Fischer I., Dittmann J., Simson G., Lynen R., Humpe A., et al. Frequency and causes of refractoriness in multiply transfused patients. Ann Hematol 1997, 74:185-189.
64. Nurden A., Combrie R., Nurden P. Detection of transfused platelets in a patient with Glanzmann thrombasthenia. Thromb Haemost 2002, 87:543-544.
65. Ito K., Yoshida H., Hatoyama H., Matsumoto H., Ban C., Mori T., et al. Antibody removal therapy used successfully at delivery of a pregnant patient with Glanzmann's thrombasthenia and multiple anti-platelet antibodies. Vox Sang 1991, 61:40-46.
66. Martin I., Kriaa F., Proulle V., Guillet B., Kaplan C., d'Oiron R., et al. Protein A Sepharose immunoadsorption can restore the efficacy of platelet concentrates in patients with Glanzmann's thrombasthenia and anti-glycoprotein IIb-IIIa antibodies. Br J Haematol 2002, 119:991-997.
67. Sundqvist S.B., Nilsson I.M., Svanberg L., Cronberg S. Pregnancy and parturition in a patient with severe Glanzmann's thrombasthenia. Scand J Haematol 1981, 27:159-164.
68. Jallu V., Pico M., Chevaleyre J., Vézon G., Kunicki T.J., Nurden A.T. Characterization of an antibody to the integrin beta 3 subunit (GP IIIa) from a patient with neonatal thrombocytopenia and an inherited deficiency of GP IIb-IIIa complexes in platelets (Glanzmann's thrombasthenia). Hum Antibodies Hybridomas 1992, 3:93-106.
69. Boval B., Bellucci S., Boyer-Neumann C., d'Oiron R., Ciraru-Vigneron N., Audibert F., et al. Glanzmann thrombasthenia and pregnancy: clinical observations and management of four affected women. Supplement to the journal Thrombosis and Haemostasis July 2001, (ISSN 0340-6245). [Abstract P1154].
70. Siddiq S., Clark A., Mumford A. A systematic review of the management and outcomes of pregnancy in Glanzmann thrombasthenia. Haemophilia 2011, 17:e858-e869.
71. Agersø H., Brophy D.F., Pelzer H., Martin E.J., Carr M., Hedner U., et al. Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patients. J Thromb Haemost 2011, 9:333-338.
72. Villar A., Aronis S., Morfini M., Santagostino E., Auerswald G., Thomsen H.F., et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia 2004, 10:352-359.
73. Berrettini M., Mariani G., Schiavoni M., Rocino A., Di Paolantonio T., Longo G., et al. Pharmacokinetic evaluation of recombinant, activated factor VII in patients with inherited factor VII deficiency. Haematologica 2001, 86:640-645.
74. Zotz R., di Minno G., d'Oiron R., Poon M.-C. The international prospective Glanzmann's Thrombasthenia Registry (GTR) special issues in children [abstract]. Blood 2012, 120:3341.
75. Seested T., Appa R.S., Christensen E.I., Ioannou Y.A., Krogh T.N., Karpf D.M., et al. In vivo clearance and metabolism of recombinant activated factor VII (rFVIIa) and its complexes with plasma protease inhibitors in the liver. Thromb Res 2011, 127:356-362.
76. Gopalakrishnan R., Hedner U., Ghosh S., Nayak R.C., Allen T.C., Pendurthi U.R., et al. Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa). J Thromb Haemost 2010, 8:301-310.
77. Reverter J.C., Béguin S., Kessels H., Kumar R., Hemker H.C., Coller B.S. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J Clin Invest 1996, 98:863-874.
78. Dargaud Y., Bordet J.C., Trzeciak M.C., Vinciguerra C., Negrier C. A case of Glanzmann's thrombasthenia successfully treated with recombinant factor viia during a surgical procedure: observations on the monitoring and the mechanism of action of this drug. Haematologica 2006, 91(6 Suppl):e58-e61.
79. He S., Blomback M., Jacobsson E.G., Hedner U. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. J Thromb Haemost 2003, 1:1215-1219.
80. He S., Ekman G.J., Hedner U. The effect of platelets on fibrin gel structure formed in the presence of recombinant factor VIIa in hemophilia plasma and in plasma from a patient with Glanzmann thrombasthenia. J Thromb Haemost 2005, 3:272-279.
81. Lopez-Vilchez I., Hedner U., Altisent C., Diaz-Ricart M., Escolar G., Galan A.M. Redistribution and hemostatic action of recombinant activated factor VII associated with platelets. Am J Pathol 2011, 178:2938-2948.
82. Proulle V., Hugel B., Guillet B., Trichet C., Rafowicz A., Lambert T., et al. Injection of recombinant activated factor VII can induce transient increase in circulating procoagulant microparticles. Thromb Haemost 2004, 91:873-878.
83. Flood V.H., Johnson F.L., Boshkov L.K., Thomas G.A., Nugent D.J., Bakke A.C., et al. Sustained engraftment post bone marrow transplant despite anti-platelet antibodies in Glanzmann thrombasthenia. Pediatr Blood Cancer 2005, 45:971-975.
84. Bellucci S., Devergie A., Gluckman E., Tobelem G., Lethielleux P., Benbunan M., et al. Complete correction of Glanzmann's thrombasthenia by allogeneic bone-marrow transplantation. Br J Haematol 1985, 59:635-641.
85. Bellucci S., Damaj G., Boval B., Rocha V., Devergie A., Yacoub-Agha I., et al. Bone marrow transplantation in severe Glanzmann's thrombasthenia with antiplatelet alloimmunization. Bone Marrow Transplant 2000, 25:327-330.
86. Connor P., Khair K., Liesner R., Amrolia P., Veys P., Ancliff P., et al. Stem cell transplantation for children with Glanzmann thrombasthenia. Br J Haematol 2008, 140:568-571.
87. Ishaqi M.K., El-Hayek M., Gassas A., Khanani M., Trad O., Baroudi M., et al. Allogeneic stem cell transplantation for Glanzmann thrombasthenia. Pediatr Blood Cancer 2009, 52:682-683.
88. Johnson A., Goodall A.H., Downie C.J., Vellodi A., Michael D.P. Bone marrow transplantation for Glanzmann's thrombasthenia. Bone Marrow Transplant 1994, 14:147-150.
89. Kitko C.L., Levine J.E., Matthews D.C., Carpenter P.A. Successful unrelated donor cord blood transplantation for Glanzmann's thrombasthenia. Pediatr Transplant 2011, 15:e42-e46.
90. McColl M.D., Gibson B.E. Sibling allogeneic bone marrow transplantation in a patient with type I Glanzmann's thrombasthenia. Br J Haematol 1997, 99:58-60.
91. Wiegering V., Winkler B., Langhammer F., Wolfl M., Wirbelauer J., Sauer K., et al. Allogeneic hematopoietic stem cell transplantation in Glanzmann thrombasthenia complicated by platelet alloimmunization. Klin Padiatr 2011, 223:173-175.
92. Fujimoto T.T., Kishimoto M., Ide K., Mizushima M., Mita M., Sezaki N., et al. Glanzmann thrombasthenia with acute myeloid leukemia successfully treated by bone marrow transplantation. Int J Hematol 2005, 81:77-80.
93. Wilcox D.A., Olsen J.C., Ishizawa L., Bray P.F., French D.L., Steeber D.A., et al. Megakaryocyte-targeted synthesis of the integrin beta(3)-subunit results in the phenotypic correction of Glanzmann thrombasthenia. Blood 2000, 95:3645-3651.
94. Fang J., Hodivala-Dilke K., Johnson B.D., Du L.M., Hynes R.O., White G.C., et al. Therapeutic expression of the platelet-specific integrin, alphaIIbbeta3, in a murine model for Glanzmann thrombasthenia. Blood 2005, 106:2671-2679.
95. Fang J., Jensen E.S., Boudreaux M.K., Du L.M., Hawkins T.B., Koukouritaki S.B., et al. Platelet gene therapy improves hemostatic function for integrin alphaIIbbeta3-deficient dogs. Proc Natl Acad Sci U S A 2011, 108:9583-9588.
96. Sullivan S.K., Mills J.A., Koukouritaki S.B., Vo K.K., Lyde R.B., Paluru P., et al. High-level transgene expression in induced pluripotent stem cell-derived megakaryocytes: correction of Glanzmann thrombasthenia. Blood 2014, 123:753-757.